Enfuvirtide (Fuzeon)
PeptideEnfuvirtide is a 36-amino acid synthetic peptide and the first FDA-approved HIV fusion inhibitor (2003). Derived from gp41, it blocks HIV entry into CD4 cells. Phase III trials showed superior viral suppression vs background regimen alone in treatment-experienced patients. Administered as 90mg subcutaneous injection twice daily.
Quick Answer
What it is
Enfuvirtide is a 36-amino acid synthetic peptide and the first FDA-approved HIV fusion inhibitor (2003). Derived from gp41, it blocks HIV entry into CD4 cells.
Key findings
- Grade A: Viral Load Reduction (HIV Infection)
- Grade A: CD4 Count Improvement (HIV Infection)
- Grade A: Treatment-Experienced Efficacy (HIV Infection)
Safety
No specific caution or interaction language was detected in the current summary/outcome notes.
⚠️ Research Notice
This peptide information is for educational and research purposes only. Peptides may not be FDA-approved for human use and may only be legally available for research purposes. Consult qualified healthcare professionals before considering any peptide compounds.
ℹ️ Quick Facts: Enfuvirtide (Fuzeon)
Quick Facts: Enfuvirtide (Fuzeon)
- Best Evidence:Grade A
- Conditions Studied:1
- Research Outcomes:9
- Grade A Findings:5
- Grade B Findings:2
- Key Effect:HIV Infection